Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections

Vaccine

Volumn 30, Issue 2, 2012, Pages 218-224

  Horácio, Andreia N ^a   Diamantino Miranda, Jorge ^a   Aguiar, Sandra I ^a   Ramirez, Mário ^a   Melo Cristino, José ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Antimicrobial resistance; Conjugate vaccines; Polysaccharide vaccine; Streptococcus pneumoniae

Indexed keywords

13 VALENT CONJUGATE STREPTOCOCCUS VACCINE; 23 VALENT POLYSACCHARIDE STREPTOCOCCUS VACCINE; 7 VALENT CONJUGATE STREPTOCOCCUS VACCINE; CEFOTAXIME; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; STREPTOCOCCUS VACCINE; TETRACYCLINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DISEASE ASSOCIATION; HUMAN; INVASIVE PNEUMOCOCCAL INFECTION; NONHUMAN; PNEUMOCOCCAL INFECTION; PORTUGAL; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PNEUMONIAE SEROTYPE 1; STREPTOCOCCUS PNEUMONIAE SEROTYPE 14; STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A; STREPTOCOCCUS PNEUMONIAE SEROTYPE 3; STREPTOCOCCUS PNEUMONIAE SEROTYPE 7F;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PORTUGAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84355161924     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.022     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-8):1-24.
2. Michel J.P., Gusmano M., Blank P.R., Philp I. Vaccination and healthy ageing: how to make life-course vaccination a successful public health strategy. Eur Geriatr Med 2010, 1(3):155-165.
3. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
4. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, (1):CD000422.
5. Fedson D.S., Nicolas-Spony L., Klemets P., van der Linden M., Marques A., Salleras L., et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011, 10(8):1143-1167.
6. Sousa M., Cavadas L.F., Santos R.B., Macedo A. Quality evaluation of the prescription of the anti-pneumococcal vaccine in the elderly. Revista Portuguesa de Clínica Geral 2009, 25:531-536.
7. Aguiar S.I., Brito M.J., Gonçalo-Marques J., Melo-Cristino J., Ramirez M. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 2010, 28(32):5167-5173. the Portuguese Group for the Study of Streptococcal Infections and the Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society.
8. Bettinger J.A., Scheifele D.W., Kellner J.D., Halperin S.A., Vaudry W., Law B., et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010, 28(9):2130-2136.
9. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46(2):174-182.
10. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
11. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16(5):816-823.
12. Centers for Disease Control and Prevention Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-11):1-18.
13. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006, 193(11):1487-1494.
14. Ardanuy C., Tubau F., Pallares R., Calatayud L., Dominguez M.A., Rolo D., et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009, 48(1):57-64.
15. Pérez-Trallero E., Marimon J.M., Ercibengoa M., Vicente D., Perez-Yarza E.G. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 2009, 28(7):731-738.
16. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., Ramirez M. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008, 14(9):835-843.
17. Sá-Leão R., Nunes S., Brito-Avô A., Frazão N., Simões A.S., Crisóstomo M.I., et al. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect 2009, 15(11):1002-1007.
18. 14-230 clone as a cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 2010, 48(1):101-108.
19. Rosen J.B., Thomas A.R., Lexau C.A., Reingold A., Hadler J.L., Harrison L.H., et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis 2011, 53(2):137-143.
20. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50(3):329-337.
21. Fenoll A., Granizo J.J., Aguilar L., Giménez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47(4):1012-1020.
22. Imöhl M., Reinert R.R., van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin Microbiol Infect 2009, 15(11):1008-1012.
23. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011, 52(5):633-640.
24. Hak E., Grobbee D.E., Sanders E.A., Verheij T.J., Bolkenbaas M., Huijts S.M., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66(9):378-383.
25. Serrano I., Ramirez M., Melo-Cristino J. Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy. Clin Microbiol Infect 2004, 10(7):652-656.
26. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing - eighteenth informational supplement 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
27. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing - seventeenth informational supplement 2007, Clinical and Laboratory Standards Institute, Wayne, PA.
28. Melo-Cristino J., Ramirez M., Serrano N., Hanscheid T. Macrolide resistance in Streptococcus pneumoniae isolated from patients with community-acquired lower respiratory tract infections in Portugal: results of a 3-year (1999-2001) multicenter surveillance study. Microb Drug Resist 2003, 9(1):73-80.
29. Carriço J.A., Silva-Costa C., Melo-Cristino J., Pinto F.R., de Lencastre H., Almeida J.S., et al. Illustration of a common framework for relating multiple typing methods by application to macrolide-resistant Streptococcus pyogenes. J Clin Microbiol 2006, 44(7):2524-2532.
30. Pinto F.R., Melo-Cristino J., Ramirez M. A confidence interval for the Wallace coefficient of concordance and its application to microbial typing methods. PLoS ONE 2008, 3(11):e3696.
31. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approch to multiple testing. J R Stat Soc Ser B Stat Method 1995, 57:289-300.
32. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing - twenty-first informational supplement 2011, Clinical and Laboratory Standards Institute, Wayne, PA.
33. Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kuhlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459.
34. Serrano I., Melo-Cristino J., Carriço J.A., Ramirez M. Characterization of the genetic lineages responsible for pneumococcal invasive disease in Portugal. J Clin Microbiol 2005, 43(4):1706-1715.
35. Marimón J.M., Ercibengoa M., Alonso M., Zubizarreta M., Pérez-Trallero E. Clonal structure and 21-year evolution of Streptococcus pneumoniae serotype 1 isolates in northern Spain. Clin Microbiol Infect 2009, 15(9):875-877.
36. Sá-Leão R., Pinto F., Aguiar S., Nunes S., Carriço J.A., Frazão N., et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J. Clin. Microbiol. 2011, 49(4):1369-1375.
37. Esteva C., Selva L., de Sevilla M.F., Garcia-Garcia J.J., Pallares R., Muñoz-Almagro C. Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008). Clin Microbiol Infect 2011, 17(9):1441-1444.